This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Abu-Shakra, M Articles by Shoenfeld, Y Search for Related Content PubMed PubMed Citation Articles by Abu-Shakra, M Articles by Shoenfeld, Y Social Bookmarking                         What's this?

xAzathioprine therapy for patients with systemic lupus erythematosus

Rheumatic Diseases Unit and Department of Medicine D,Soroka Medical Center, Ben-Gurion University, Beer-Sheva, Israel

Y Shoenfeld

Department of Medicine B, and Research Unit of Autoimmune Diseases, Tel-Hashomer Medical Center and Tel-Aviv University, Tel-Aviv, Israel

Azathioprine is the only purine analog that is widely used for the management of systemic lupus erythematosus (SLE). For SLE patients without renal involvement, it is given to those patients who require a maintenance dose of 15 mg or higher of prednisone and for those who experience recurrent flares. Azathioprine in combination with steroids may be given to a large number of patients with lupus nephritis. It is also effective for patients with skin lesions, pneumonitis, thrombocytopenia or hemolytic anemia. Azathioprine may be used during pregnancy but not during lactation. It has not been shown to increase the risk for the development of malignancies among patients with SLE.

Key Words: azathioprine • SLE • Immunosuppression

Lupus, Vol. 10, No. 3, 152-153 (2001)
DOI: 10.1191/096120301676669495


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Panjwani Early Diagnosis and Treatment of Discoid Lupus Erythematosus J Am Board Fam Med, March 1, 2009; 22(2): 206 - 213. [Abstract] [Full Text] [PDF]

				C Flower, A Hennis, I R Hambleton, and G Nicholson Lupus nephritis in an Afro-Caribbean population: renal indices and clinical outcomes Lupus, October 1, 2006; 15(10): 689 - 694. [Abstract] [PDF]

				C A Pineau, S Bernatsky, M Abrahamowicz, C Neville, I Karp, and A E Clarke A comparison of damage accrual across different calendar periods in systemic lupus erythematosus patients Lupus, September 1, 2006; 15(9): 590 - 594. [Abstract] [PDF]

				A Mak and C C Mok Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus Lupus, October 1, 2005; 14(10): 856 - 858. [Abstract] [PDF]

				S. Bernatsky, R. Ramsey-Goldman, C. Gordon, L. Joseph, J.-F. Boivin, R. Rajan, A. Allen, A. D. Moore, M.-H. Leung, and A. Clarke Factors associated with abnormal Pap results in systemic lupus erythematosus Rheumatology, November 1, 2004; 43(11): 1386 - 1389. [Abstract] [Full Text] [PDF]

				M. A. Kamal and W. J. Jusko Interactions of Prednisolone and Other Immunosuppressants Used in Dual Treatment of Systemic Lupus Erythematosus in Lymphocyte Proliferation Assays J. Clin. Pharmacol., September 1, 2004; 44(9): 1034 - 1045. [Abstract] [Full Text] [PDF]

				M A. Ramos, C. Pinera, M A. Setien, L. Buelta, M A. de Cos, A.-L. M. de Francisco, R. Merino, and M. Arias Modulation of autoantibody production by mycophenolate mofetil: effects on the development of SLE in (NZBxNZW)F1 mice Nephrol. Dial. Transplant., May 1, 2003; 18(5): 878 - 883. [Abstract] [Full Text] [PDF]